Laura Alonso

Laura Alonso is the E. Hugh Luckey Distinguished Professor of Medicine and Professor of Medicine at Weill Cornell Medical College, Cornell University. Her primary affiliation is with the Department of Medicine, focusing on diabetes, endocrinology, and metabolic disorders. She holds dual degrees: an M.D. from the University of Pennsylvania School of Medicine (1998) and a B.A. from Harvard College (1993).

Her research emphasizes pancreatic β-cell biology, endoplasmic reticulum (ER) stress pathways, and diabetes management strategies. Notable areas include the role of adipose tissue in metabolic dysfunction, telemedicine applications in diabetes care, and mechanisms of β-cell proliferation and survival. Her recent work explores interventions like carbohydrates-last food ordering to improve glycemic control and the impact of SARS-CoV-2 on adipose tissue and insulin resistance during acute infections.

Dr. Alonso leads NIH-funded grants, including 'Research Training in Endocrinology and Metabolism' (2023–2028) and 'Role of Polyamines and Hypusine in Nutrient-Induced Beta-Cell Growth' (2020–2025). Her publications span over three decades, with breakthroughs in β-cell signaling (e.g., CDK4, ATF6 pathways) and clinical trials like the ergocalciferol treatment for type 1 diabetes.

Collaborations include work with Eli Lilly and Company, reflecting her translational focus. She is board-certified in Internal Medicine and Endocrinology, Diabetes, and Metabolism, with clinical expertise in diabetes subtypes, prediabetes, and metabolic disorders.